^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Anktiva (nogapendekin alfa inbakicept-pmln)

    i
    Other names: N-803, IL-15N72D:IL-15RαSu/IgG1 Fc complex, ALT-803, IL-15N72D:IL-15RαSu/Fc fusion protein complex, ALT 803
    Company:
    ImmunityBio
    Drug class:
    IL-15 superagonist
    Related drugs:
    4d
    3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803) (clinicaltrials.gov)
    P1, N=28, Active, not recruiting, Rockefeller University | Trial completion date: Dec 2025 --> Mar 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    4d
    Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Washington University School of Medicine | Trial completion date: Sep 2026 --> Mar 2028 | Trial primary completion date: Sep 2026 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • Anktiva (nogapendekin alfa inbakicept-pmln)
    4d
    QUILT-88: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=328, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Oct 2025 --> May 2026
    Trial completion date
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK • aldoxorubicin (INNO-206)
    8d
    QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    16d
    N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy (clinicaltrials.gov)
    P1, N=8, Not yet recruiting, Northwestern University
    New P1 trial
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    29d
    Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov)
    P1/2, N=60, Recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2028 --> Oct 2030 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Zynyz (retifanlimab-dlwr) • SX-682 • Anktiva (nogapendekin alfa inbakicept-pmln)
    29d
    CARMEN-803: N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=13, Not yet recruiting, University of Utah | Initiation date: Sep 2025 --> Dec 2025
    Trial initiation date
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    2ms
    N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P2, N=34, Recruiting, ImmunityBio, Inc. | Active, not recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    2ms
    Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, ImmunityBio, Inc. | Trial completion date: May 2029 --> Nov 2029 | Initiation date: May 2025 --> Nov 2025 | Trial primary completion date: May 2026 --> Nov 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    gemcitabine • Anktiva (nogapendekin alfa inbakicept-pmln)
    2ms
    QUILT2023: Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1538, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln)
    3ms
    A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov)
    P2, N=54, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CSF2 (Colony stimulating factor 2)
    |
    temozolomide • irinotecan • Anktiva (nogapendekin alfa inbakicept-pmln) • Leukine (sargramostim) • humanised dinutuximab (Hu14.18K322A)
    3ms
    Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Sep 2026 | Trial primary completion date: Jan 2027 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • Anktiva (nogapendekin alfa inbakicept-pmln)